Education
About Us
Working with TipRanks
Follow Us
Kevin D. Freeman Insider Profile
4 Followers
Kevin D. Freeman, Director at Galectin Therapeutics, holds 147.83K shares in Galectin Therapeutics (Ticker: GALT). Most recently, Kevin D. Freeman Bought $5,000 shares of Galectin Therapeutics on Jul 18, 2025 for an estimated value of 14.45K.
Kevin D. Freeman Galectin Therapeutics (GALT)Director
Galectin Therapeutics (GALT)
Director
Ranked #38,179 out of 102,830 Corporate Insiders
Profitable Transactions
12 out of 29 Profitable Transactions
Average Return
+0.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Kevin D. Freeman's holdings
Insider Roles
Director
Roles that Kevin D. Freeman holds in companies
Most Profitable Insider Trade
The most profitable trade made by Kevin D. Freeman
Kevin D. Freeman's Trading History
List of latest transactions for each holding click on a transaction to see Kevin D. Freeman's performance on stock
You May Also Like
Kevin D. Freeman insider profile FAQ
What is the percentage of profitable transactions made by Kevin D. Freeman?
The percentage of profitable transactions made by Kevin D. Freeman is 41%.
What is the average return per transaction made by Kevin D. Freeman?
The average return per transaction made by Kevin D. Freeman is 0.80%.
What stocks does Kevin D. Freeman hold?
Kevin D. Freeman holds: GALT stocks.
What was Kevin D. Freeman’s latest transaction?
Kevin D. Freeman latest transaction was an Informative Buy of $14.45K.
What was Kevin D. Freeman's most profitable transaction?
Kevin D. Freeman’s most profitable transaction was an Informative Buy of GALT stock on December 26, 2024. The return on the trade was 319.50%.
What is Kevin D. Freeman's role in Galectin Therapeutics?
Kevin D. Freeman's role in Galectin Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.